Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
This article was originally published in The Pink Sheet Daily
Sanofi will take a 12% stake in Alnylam for $700 million in a transformative deal that revalidates the biotech’s RNAi technology platform after the company lost important big pharma partners three years ago. The announcement Jan. 13 kicked off the opening of the JP Morgan Healthcare conference.
You may also be interested in...
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
Biomedical researchers are rapidly adopting the new gene-editing technology CRISPR/Cas9 for lab experiments, but can CRISPR also become the basis for new treatments of human disease? At least two venture-backed start-ups can't wait to find out.